What is Minipril?
Minipril is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure can reduce the risk of strokes and heart attacks.
Minipril is an angiotensin converting enzyme (ACE) inhibitor. It works by blocking a substance in the body that causes the blood vessels to tighten. As a result, Minipril relaxes the blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart.
Minipril is also used in combination with other medicines to treat congestive heart failure and cut down on the number of hospital visits for heart problems.
Minipril is available only with your doctor's prescription..
Minipril indications
Hypertension
Minipril is indicated for the treatment of hypertension.
Minipril is effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. The blood pressure lowering effects of Minipril and thiazides are approximately additive.
Heart Failure
Minipril is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients Minipril improves symptoms, increases survival, and decreases the frequency of hospitalization.
Asymptomatic Left Ventricular Dysfunction
In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤ 35 percent), Minipril decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure.
In using Minipril consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that Minipril does not have a similar risk.
In considering use of Minipril, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks.
How should I use Minipril?
Use Minipril solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Minipril solution by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
- Shake well before each use.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- Continue to take Minipril solution even if you feel well. Do not miss any doses.
- If you miss a dose of Minipril solution, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Minipril solution.
Uses of Minipril in details
Minipril is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat heart failure and to help prevent people with a certain heart problem (left ventricular dysfunction) from developing heart failure.
Minipril belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
This medication may also be used to help protect the kidneys from harm due to diabetes.
How to use Minipril
Take this medication by mouth with or without food as directed by your doctor, usually once or twice daily.
If you are using the suspension form of this medication, shake the bottle well before each dose. Carefully measure the dose using a special measuring device/spoon. Do not use a household spoon because you may not get the correct dose.
The dosage is based on your medical condition and response to treatment. For children, the dosage is also based on weight.
Use this medication regularly in order to get the most benefit from it. To help you remember, take it at the same time(s) each day. It is important to continue taking this medication even if you feel well. Most people with high blood pressure do not feel sick.
For the treatment of high blood pressure, it may take several weeks before you get the full benefit of this medication. For the treatment of heart failure, it may take weeks to months before you get the full benefit of this medication. Tell your doctor if your condition does not improve or if it worsens (such as your blood pressure readings remain high or increase).
Minipril description
Minipril MALEATE (Minipril) is available for oral administration as tablets containing Minipril maleate 5 mg, 10 mg and 20 mg.
Minipril MALEATE (Minipril) is the maleate salt of Minipril, a derivative of two amino-acids, L-alanine and L-proline. Following oral administration, Minipril is rapidly absorbed and then hydrolyzed to enalaprilat, which is a highly specific, long-acting, non-sulphydryl angiotensin converting enzyme inhibitor.
Tablets Minipril MALEATE (Minipril) contain the maleate salt of Minipril, the ethyl ester of the parent diacid, enalaprilat. Minipril maleate is chemically described as (S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline, (Z)-2-butenedioate salt (1:1). The empirical formula is C20H28N205·C4H4O4.
Minipril maleate is a white to off-white crystalline powder with a molecular weight of 492.53. It is sparingly soluble in water, soluble in ethanol, and freely soluble in methanol and dimethylformamide.
Minipril dosage
Since absorption of Tablets Minipril MALEATE (Minipril) is not affected by food, the tablets may be administered before, during, or after meals.
Essential Hypertension: The initial dose is 10 to 20 mg, depending on the degree of hypertension, and is given once daily. In mild hypertension the recommended initial dose is 10 mg daily. For other degrees of hypertension the initial dose is 20 mg daily. The usual maintenance dose is one 20 mg tablet taken once daily. The dosage should be adjusted according to the needs of the patient to a maximum of 40 mg daily.
Renovascular Hypertension: Since blood pressure and renal function in such patients may be particularly sensitive to ACE inhibition, therapy should be initiated with a lower starting dose (e.g. 5 mg or less). The dosage should then be adjusted according to the needs of the patient. Most patients may be expected to respond to one 20 mg tablet taken once daily. For patients with hypertension who have been treated recently with diuretics, caution is recommended.
Concomitant Diuretic Therapy in Hypertension: Symptomatic hypotension may occur following the initial dose of Minipril MALEATE (Minipril); this is more likely in patients who are being treated currently with diuretics. Caution is recommended, therefore, since these patients may be volume- or salt-depleted. The diuretic therapy should be discontinued for 2-3 days prior to initiation of therapy with Minipril MALEATE (Minipril). If this is not possible, the initial dose of Minipril MALEATE (Minipril) should be low (5 mg or less) to determine the initial effect on the blood pressure. Dosage should then be adjusted according to the needs of the patient.
Dosage in Renal Insufficiency: Generally, the intervals between the administration of Minipril should be prolonged and/or the dosage reduced.
Heart Failure/Asymptomatic Left Ventricular Dysfunction: The initial dose of Minipril MALEATE (Minipril) in patients with symptomatic heart failure or asymptomatic left ventricular dysfunction is 2.5 mg, and it should be administered under close medical supervision to determine the initial effect on the blood pressure. Minipril MALEATE (Minipril) may be used in the management of symptomatic heart failure usually with diuretics and, where appropriate, digitalis. In the absence of, or after effective management of, symptomatic hypotension following initiation of therapy with Minipril MALEATE (Minipril) in heart failure, the dose should be increased gradually to the usual maintenance dose of 20 mg, given in a single dose or two divided doses, as tolerated by the patient. This dose titration may be performed over a 2 to 4 week period, or more rapidly if indicated by the presence of residual signs and symptoms of heart failure. In patients with symptomatic heart failure, this dosage regimen was effective in reducing mortality.
Blood pressure and renal function should be monitored closely both before and after starting treatment with Minipril MALEATE (Minipril) because hypotension and (more rarely) consequent renal failure have been reported. In patients treated with diuretics, the dose should be reduced if possible before beginning treatment with Minipril MALEATE (Minipril). The appearance of hypotension after the initial dose of Minipril MALEATE (Minipril) does not imply that hypotension will recur during chronic therapy with Minipril MALEATE (Minipril) and does not preclude continued use of the drug. Serum potassium also should be monitored.
Administration: Minipril MALEATE (Minipril) is available for oral administration as tablets. Since absorption of Tablets Minipril MALEATE (Minipril) is not affected by food, the tablets, may be administered before, during, or after meals.
Minipril interactions
See also:
What other drugs will affect Minipril?
Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Minipril or enalaprilat. The possibility of hypotensive effects with Minipril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Minipril or enalaprilat. If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour..
Agents Causing Renin Release: The antihypertensive effect of Minipril and Minipril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of Minipril may result in a further deterioration of renal function. These effects are usually reversible.
In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving Minipril. In this study there was no evidence of a blunting of the antihypertensive action of Minipril. However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
Other Cardiovascular Agents: Minipril Bp and Minipril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
Minipril Bp IV has been used concomitantly with digitalis without evidence of clinically significant adverse reactions.
Agents Increasing Serum Potassium: Minipril Bp and Minipril IV attenuate potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Potassium sparing agents should generally not be used in patients with heart failure receiving Minipril.
Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant Minipril/Minipril IV and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if Minipril is administered concomitantly with lithium.
Minipril side effects
See also:
What are the possible side effects of Minipril?
Minipril MALEATE (Minipril) has been demonstrated to be generally well tolerated. In clinical studies, the overall incidence of side effects was no greater with Minipril MALEATE (Minipril) than with placebo. For the most part, side effects have been mild and transient in nature, and have not required discontinuation of therapy.
The following side effects have been associated with the use of Tablets Minipril MALEATE (Minipril): Dizziness and headache were the more commonly reported side effects. Fatigue and asthenia were reported in 2-3% of patients. Other side effects occurred in less than 2% of patients, and included hypotension, orthostatic hypotension, syncope, nausea, diarrhea, muscle cramps, rash, and cough. Less frequently renal dysfunction, renal failure, and oliguria have been reported.
Hypersensitivity/Angioneurotic Edema: Angioneurotic edema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely. In very rare cases, intestinal angioedema has been reported with angiotensin converting enzyme inhibitors including Minipril.
Side effects which occurred very rarely, either during controlled clinical trials or after the drug was marketed, include: Cardiovascular: Myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients, chest pain, palpitations, rhythm disturbances, angina pectoris, Raynaud's phenomenon.
Endocrine: Syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Gastrointestinal: Ileus, pancreatitis, hepatic failure, hepatitis - either hepatocellular or cholestatic, jaundice, abdominal pain, vomiting, dyspepsia, constipation, anorexia, stomatitis.
Metabolic: Cases of hypoglycemia in diabetic patients on oral antidiabetic agents or insulin have been reported.
Nervous System/Psychiatric: Depression, confusion, somnolence, insomnia, nervousness, paresthesia, vertigo, dream abnormality.
Respiratory: Pulmonary infiltrates, bronchospasm/asthma, dyspnea, rhinorrhea, sore throat and hoarseness.
Skin: Diaphoresis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, pemphigus, pruritus, urticaria, alopecia.
Other: Impotence, flushing, taste alteration, tinnitus, glossitis, blurred vision.
A symptom complex has been reported which may include some or all of the following: Fever, serositis, vasculitis, myalgia/myositis, arthralgia/arthritis, a positive ANA, elevated ESR, eosinophilia, and leukocytosis. Rash, photosensitivity or other dermatologic manifestations may occur.
Laboratory Test Findings: Clinically important changes in standard laboratory parameters were rarely associated with administration of Minipril MALEATE (Minipril). Increases in blood urea and serum creatinine, and elevations of liver enzymes and/or serum bilirubin have been seen. These are usually reversible upon discontinuation of Minipril MALEATE (Minipril). Hyperkalemia and hyponatremia have occurred.
Decreases in hemoglobin and hematocrit have been reported.
Since the drug was marketed a small number of cases of neutropenia, thrombocytopenia, bone marrow depression, and agranulocytosis have been reported in which a causal relationship to therapy with Minipril MALEATE (Minipril) could not be excluded.
Minipril contraindications
See also:
What is the most important information I should know about Minipril?
Do not use this medication if you are pregnant. Stop using this medication and tell your doctor right away if you become pregnant.
You should not use this medication if you are allergic to Minipril, or similar medicines such as such as benazepril (Lotensin), captopril (Capoten Capozide), fosinopril (Monopril), lisinopril (Prinivil, Prinzide, Zestoretic, Zestril), moexipril (Univasc, Uniretic), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik, Tarka), and others.
Before you take Minipril, tell your doctor if you have kidney or liver disease, heart disease, diabetes, or a connective tissue disease such as Marfan syndrome, Sjogren's syndrome, lupus, scleroderma, or rheumatoid arthritis.
Tell your doctor about all other medicines you use.
Conditions that may cause very low blood pressure include: vomiting, diarrhea, heavy sweating, heart disease, dialysis, a low salt diet, or taking diuretics (water pills). Follow your doctor's instructions about the type and amount of liquids you should drink while taking Minipril. Tell your doctor if you have a prolonged illness that causes diarrhea or vomiting.
If you need surgery, tell the surgeon ahead of time that you are using Minipril. You may need to stop using the medicine for a short time. Your blood pressure will need to be checked often. Your kidney or liver function may also need to be tested. Visit your doctor regularly.
Active ingredient matches for Minipril:
Enalapril in Bangladesh, India, Myanmar, Sri Lanka.
| Unit description / dosage (Manufacturer) | Price, USD |
| MINIPRIL Capsule/ Tablet / 2.5mg / 10 units (Alembic) | $ 0.19 |
| MINIPRIL Capsule/ Tablet / 5mg / 10 units (Alembic) | $ 0.34 |
| Minipril 2.5mg TAB / 10 | |
| Minipril 5mg TAB / 10 | |
| Minipril 100mg TAB / 10 | $ 0.36 |
| 2.5 mg x 10's | |
| 5 mg x 10's | |
| 10 mg x 10's | $ 0.36 |
| MINIPRIL 10 MG TABLET 1 strip / 10 tablets each (Alembic Pharmaceuticals Ltd) | $ 0.36 |
| MINIPRIL 2.5 MG TABLET 1 strip / 10 tablets each (Alembic Pharmaceuticals Ltd) | $ 1.36 |
| MINIPRIL 5 MG TABLET 1 strip / 10 tablets each (Alembic Pharmaceuticals Ltd) | $ 0.08 |
| MINIPRIL tab 2.5 mg x 10's (Alembic) | $ 0.13 |
| MINIPRIL tab 5 mg x 10's (Alembic) | $ 0.19 |
| MINIPRIL tab 10 mg x 10's (Alembic) | $ 0.36 |
| Minipril 10mg Tablet (Alembic Pharmaceuticals Ltd) | $ 0.04 |
| Minipril 2.5mg Tablet (Alembic Pharmaceuticals Ltd) | $ 0.14 |
| Minipril 5mg Tablet (Alembic Pharmaceuticals Ltd) | $ 0.01 |
List of Minipril substitutes (brand and generic names): | |
| Mepril 5 mg (Austria) | |
| Multipressim (Brazil) | |
| Mylan-Enalapril (Canada) | |
| Tablet; Oral; Enalapril Sodium 16 mg | |
| Tablet; Oral; Enalapril Sodium 2 mg | |
| Tablet; Oral; Enalapril Sodium 4 mg | |
| Tablet; Oral; Enalapril Sodium 8 mg | |
| Tablets; Oral; Enalapril Sodium 16 mg | |
| Tablets; Oral; Enalapril Sodium 2 mg | |
| Tablets; Oral; Enalapril Sodium 4 mg | |
| Tablets; Oral; Enalapril Sodium 8 mg | |
| Mylan-enalapril tablet 16 mg (Mylan Pharmaceuticals Ulc (Canada)) | |
| Mylan-enalapril tablet 2 mg (Mylan Pharmaceuticals Ulc (Canada)) | |
| Mylan-enalapril tablet 4 mg (Mylan Pharmaceuticals Ulc (Canada)) | |
| Mylan-enalapril tablet 8 mg (Mylan Pharmaceuticals Ulc (Canada)) | |
| Myoace (India) | |
| MYOACE Capsule/ Tablet / 10mg / 10 units (Merck) | $ 0.34 |
| MYOACE Capsule/ Tablet / 5mg / 10 units (Merck) | $ 0.21 |
| MYOACE Capsule/ Tablet / 2.5mg / 10 units (Merck) | $ 0.14 |
| Myoace 2.5mg TAB / 10 (Merck) | $ 0.11 |
| Myoace 5mg TAB / 10 (Merck) | $ 0.20 |
| Myoace 10mg TAB / 10 (Merck) | $ 0.33 |
| 2.5 mg x 10's (Merck) | $ 0.11 |
| 5 mg x 10's (Merck) | $ 0.20 |
| 10 mg x 10's (Merck) | $ 0.33 |
| MYOACE 2.5MG TABLET 1 strip / 10 tablets each (Merck) | $ 0.15 |
| MYOACE 5MG TABLET 1 strip / 10 tablets each (Merck) | $ 0.22 |
| MYOACE tab 2.5 mg x 10's (Merck) | $ 0.11 |
| MYOACE tab 5 mg x 10's (Merck) | $ 0.20 |
| MYOACE tab 10 mg x 10's (Merck) | $ 0.33 |
| Myoace 2.5mg Tablet (Merck) | $ 0.01 |
| Myoace 5mg Tablet (Merck) | $ 0.02 |
| Myopril (Thailand) | |
| Myopril 5 mg x 10 x 10's (Unique) | |
| Myopril 10 mg x 10 x 10's (Unique) | |
| Myopril tab 10 mg 10 x 10's (Unique) | |
| Myopril tab 5 mg 10 x 10's (Unique) | |
| Nalabest (Mexico) | |
| Nalapril (Argentina) | |
| Nalaprix (Brazil) | |
| Nalopril (Thailand) | |
| Nalopril 5 mg x 100's (Siam Bheasach) | |
| Nalopril 10 mg x 100's (Siam Bheasach) | |
| Nalopril 20 mg x 100's (Siam Bheasach) | |
| Nalopril tab 10 mg 10 x 10's (Siam Bheasach) | |
| Nalopril tab 20 mg 10 x 10's (Siam Bheasach) | |
| Nalopril tab 5 mg 10 x 10's (Siam Bheasach) | |
| Napril (Israel) | |
| Tablet; Oral; Enalapril Maleate 10 mg | |
See 2281 substitutes for Minipril | |
References
- DailyMed. "ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "enalapril". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "enalapril". http://www.drugbank.ca/drugs/DB00584 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Minipril are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Minipril. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet1 consumer reported age
| Users | % | ||
|---|---|---|---|
| 46-60 | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
